Log in

NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Forecast & News

$47.34
+0.44 (+0.94 %)
(As of 03/31/2020 04:57 AM ET)
Today's Range
$46.91
Now: $47.34
$47.50
50-Day Range
$40.51
MA: $46.28
$47.56
52-Week Range
$19.64
Now: $47.34
$47.77
Volume1.21 million shs
Average Volume1.02 million shs
Market Capitalization$2.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
Ra Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$5.56 per share

Profitability

Net Income$-102,690,000.00

Miscellaneous

Employees72
Market Cap$2.24 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.


Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

How has Ra Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ra Pharmaceuticals' stock was trading at $45.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RARX shares have increased by 3.0% and is now trading at $47.34. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ra Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 10 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Ra Pharmaceuticals.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Ra Pharmaceuticals.

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) released its earnings results on Thursday, February, 27th. The company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.16. View Ra Pharmaceuticals' earnings history.

What price target have analysts set for RARX?

10 brokers have issued twelve-month target prices for Ra Pharmaceuticals' stock. Their forecasts range from $42.00 to $49.00. On average, they expect Ra Pharmaceuticals' share price to reach $47.38 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View analysts' price targets for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

Media stories about RARX stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ra Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutRa Pharmaceuticals.

Are investors shorting Ra Pharmaceuticals?

Ra Pharmaceuticals saw a increase in short interest in March. As of March 13th, there was short interest totaling 5,934,300 shares, an increase of 5.0% from the February 27th total of 5,650,000 shares. Based on an average daily trading volume, of 891,800 shares, the short-interest ratio is currently 6.7 days. Approximately 18.3% of the company's stock are short sold. View Ra Pharmaceuticals' Current Options Chain.

Who are some of Ra Pharmaceuticals' key competitors?

What other stocks do shareholders of Ra Pharmaceuticals own?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the following people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 55)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
  • Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of Research
  • Dr. Simon Read, Chief Scientific Officer (Age 48)

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $47.34.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $2.24 billion and generates $3 million in revenue each year. The company earns $-102,690,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe. View additional information about Ra Pharmaceuticals.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is http://www.rapharma.com/.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  496
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: What is a put option?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel